Craig-Hallum lowered the firm’s price target on scPharmaceuticals (SCPH) to $12 from $16 and keeps a Buy rating on the shares. The firm notes the company’s Q3 report is likely to leave investors unsatisfied. Craig-Hallum believes that it is important for investors to understand that scPharmaceuticals is now seeing more demand from IDNs/hospital systems, and this volume and revenue is not reflected in the script data provided.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCPH: